{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:18:16Z","timestamp":1781029096028,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Where previously, germline genetic testing in deceased affected relatives was not possible due to the absence of lymphocytic DNA, the North-West-Genomic-Laboratory Hub (NWGLH) has developed and validated next-generation sequencing based gene panels utilising formalin-fixed-paraffin-embedded (FFPE) tissue DNA from deceased individuals. This technology has been utilised in the clinical setting for the management of unaffected relatives seen in the Clinical Genetics Service (CGS). Here we assess the clinical impact. At the time of data collection, the NWGLH had analysed 180 FFPE tissue samples from deceased affected individuals: 134 from breast and\/or ovarian cancer cases for germline variants in the <jats:italic>BRCA1\/BRCA2<\/jats:italic> genes and 46 from colorectal, gastric, ovarian and endometrial cancer cases for germline variants in a panel of 13 genes implicated in inherited colorectal cancer and gastric cancer conditions. Successful analysis was achieved in 140\/180 cases (78%). In total, 29 germline pathogenic\/likely pathogenic variants were identified in autosomal dominant cancer predisposition genes where the gene was pertinent to the cancer family history (including <jats:italic>BRCA1\/BRCA2<\/jats:italic>, the mismatch-repair genes and <jats:italic>APC<\/jats:italic>). Of the 180 cases, the impact of the result on clinical management of unaffected relatives was known in 143 cases. Of these, the results in 54 cases (38%) directly impacted the clinical management of relatives seen by the CGS. This included changes to risk assessments, screening recommendations and the availability of predictive genetic testing to unaffected relatives. Our data demonstrate how FFPE testing in deceased relatives is an accurate and informative tool in the clinical management of patients referred to the CGS.<\/jats:p>","DOI":"10.1038\/s41431-021-00817-w","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T10:08:22Z","timestamp":1614679702000},"page":"861-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6587-8805","authenticated-orcid":false,"given":"Sarah","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-2855","authenticated-orcid":false,"given":"Emma R.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Schlecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"817_CR1","unstructured":"National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. 2013. www.nice.org.uk\/guidance\/cg164"},{"key":"817_CR2","first-page":"1","volume":"0","author":"KJ Monahan","year":"2019","unstructured":"Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop M, East J, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology\/Association of Coloproctology of Great Britain and Ireland \/United Kingdom Cancer Genetics Group. GUT. 2019;0:1\u201334.","journal-title":"GUT"},{"key":"817_CR3","doi-asserted-by":"crossref","unstructured":"Evans DG, Harkness E, Plaskocinska I, Wallace A, Clancy T, Woodward E, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families, J Med Genet. 2017;54:674\u201381.","DOI":"10.1136\/jmedgenet-2017-104584"},{"key":"817_CR4","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","volume":"21","author":"A Lee","year":"2019","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham A, Carver A, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genetic Medicine. 2019. Genet Med. 2019;21:1708\u201318.","journal-title":"Genet Med"},{"key":"817_CR5","unstructured":"National Institute for Health and Care Excellence. Colorectal cancer. 2020. https:\/\/www.nice.org.uk\/guidance\/NG151"},{"key":"817_CR6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.7150\/ijms.8842","volume":"11","author":"B Seng\u00fcven","year":"2014","unstructured":"Seng\u00fcven B, Baris E, Oygur T, Berktas M. Comparison of methods for the extraction of DNA from FFPE archival tissues. Int J Med Sci. 2014;11:494\u20139.","journal-title":"Int J Med Sci"},{"key":"817_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12907-015-0004-6","volume":"15","author":"G Ellison","year":"2015","unstructured":"Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M, Bhaskar S, et al. A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clin Pathol. 2015;15:1\u201314.","journal-title":"BMC Clin Pathol"},{"key":"817_CR8","doi-asserted-by":"crossref","unstructured":"Bhagwate A, Liu Y, Winham S, McDonough S, Stallings-Mann M, Heinzen E, et al. Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. BMC Genom. 2019;20:689","DOI":"10.1186\/s12864-019-6056-8"},{"key":"817_CR9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ejhg.2015.268","volume":"24","author":"A Petersen","year":"2016","unstructured":"Petersen A, Aagaard M, Nielsen H, Steffensen K, Waldstr\u00f8m M, Bojesen A. Post-mortem testing; germline BRCA1\/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. Eur J Hum Genet. 2016;24:1104\u201311.","journal-title":"Eur J Hum Genet"},{"key":"817_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10689-006-0003-y","volume":"5","author":"MA Adank","year":"2006","unstructured":"Adank MA, Brogi E, Bogomolniy F, Wadsworth E, Lafaro K, Yee C, et al. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer. 2006;5:337\u201342.","journal-title":"Fam Cancer"},{"key":"817_CR11","doi-asserted-by":"crossref","first-page":"e5548","DOI":"10.1371\/journal.pone.0005548","volume":"4","author":"M Schweiger","year":"2009","unstructured":"Schweiger M, Kerick M, Timmermann B, Albrecht M, Borodina T, Parkhomchuk D, et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS ONE. 2009;4:e5548.","journal-title":"PLoS ONE"},{"key":"817_CR12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"I Cree","year":"2014","unstructured":"Cree I, Deans Z, Ligtenberg M, Normanno N, Edsjo A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67:923\u201331.","journal-title":"J Clin Pathol"},{"key":"817_CR13","unstructured":"United Kingdom Accreditation Service (UKAS). www.ukas.com Accessed November 2020."},{"key":"817_CR14","unstructured":"United Kingdom National External Quality Assessment Service (UK NEQAS). https:\/\/ukneqas.org.uk."},{"key":"817_CR15","unstructured":"Human Tissue Authority. Code A: guiding principles and the fundamental principle of consent. 2017. www.hta.gov.uk\/hta-codes-practice-and-standards-0."},{"key":"817_CR16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. ACMG Laboratory Quality Assurance Committee. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"817_CR17","unstructured":"Ellard S, Baple E, Owens M, Eccles D, Turnbull C, Abbs S, et al. ACGS Best Practice Guidelines for Variant Classification. 2018. https:\/\/www.acgs.uk.com\/quality\/best-practice-guidelines\/#VariantGuidelines."},{"key":"817_CR18","unstructured":"Public Health England. NHS breast screening programme overview. 2015. https:\/\/www.gov.uk\/guidance\/breast-screening-programme-overview."},{"key":"817_CR19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10689-015-9785-0","volume":"14","author":"P James","year":"2015","unstructured":"James P, Sawyer S, Boyle S, Young M, Kovalenko S, Doherty R, et al. Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. Fam Cancer. 2015;14:287\u201395.","journal-title":"Fam Cancer"},{"key":"817_CR20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/humu.22938","volume":"37","author":"M Smith","year":"2016","unstructured":"Smith M, Urquhart J, Harkness E, Miles E, Bowers N, Byers H, et al. The contribution of whole gene deletions and large rearrangements to the mutation spectrum in inherited tumor predisposing syndromes. Hum Mutat. 2016;37:250\u20136.","journal-title":"Hum Mutat"},{"key":"817_CR21","unstructured":"National Health Service (NHS). The NHS Long Term plan. 2019. www.longtermplan.nhs.uk."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00817-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:24Z","timestamp":1684616544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00817-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1038\/s41431-021-00817-w","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}